How should I manage recurrent urinary tract infections in an 84‑year‑old woman who is already using vaginal estrogen three times weekly and D‑mannose?

Management of Recurrent UTIs in an 84-Year-Old Woman Already Using Vaginal Estrogen and D-Mannose

Add methenamine hippurate as your next step, as D-mannose has been shown ineffective in recent high-quality trials, and consider immunoactive prophylaxis or antibiotic prophylaxis if non-antimicrobial measures fail. 1, 2, 3

Current Evidence on D-Mannose

Your patient is already using D-mannose, but the most recent and highest-quality evidence demonstrates it is not effective for rUTI prevention. The 2024 JAMA trial (N=598) found no significant difference between D-mannose and placebo in preventing medically-attended UTIs (51.0% vs 55.7%, risk difference -5%, p=0.26) 3. This finding is reinforced by a 2025 systematic review showing D-mannose failed to demonstrate benefit in broad primary care populations 4. The 2025 AUA/CUA/SUFU guidelines now explicitly state that clinicians should inform patients that D-mannose alone may not be effective 2. While one older trial suggested benefit in specialist settings, the weight of recent evidence argues against continuing D-mannose as a standalone preventive strategy.

Vaginal Estrogen: Continue Current Regimen

Continue the vaginal estrogen three times weekly—this remains strongly recommended by all major guidelines 1. The 2024 EAU guidelines give vaginal estrogen a "strong" recommendation for postmenopausal women with rUTIs 1. A large retrospective study (N=5,638) demonstrated a 51.9% reduction in UTI frequency following vaginal estrogen prescription 5. The mechanism involves restoring the lactobacillus-dominant vaginal microbiome and reducing urogenital atrophy, both critical in this age group 6, 7.

Next Steps: Escalation Algorithm

First-Line Addition: Methenamine Hippurate

Add methenamine hippurate (1 gram twice daily) as your next intervention 1. The 2024 EAU guidelines give this a "strong" recommendation for women without urinary tract abnormalities 1. Methenamine works by converting to formaldehyde in acidic urine, providing non-antibiotic bacteriostatic activity. It has been shown non-inferior to daily antibiotic prophylaxis in preventing rUTIs 4. This is particularly appropriate for an 84-year-old given concerns about antibiotic resistance and the cumulative burden of repeated antibiotic courses 6.

Second-Line: Immunoactive Prophylaxis

If methenamine fails, consider immunoactive prophylaxis (OM-89/Uro-Vaxom if available in your region) 1. The 2024 EAU guidelines give this a "strong" recommendation for all age groups 1. The sublingual vaccine MV140 has shown 56-58% of women remaining UTI-free in large RCTs 4.

Third-Line: Antibiotic Prophylaxis

When non-antimicrobial interventions fail, initiate continuous low-dose antibiotic prophylaxis 1, 2. The 2024 EAU guidelines strongly recommend this approach when other measures are unsuccessful 1. Preferred agents include:

• Nitrofurantoin 50-100 mg daily (first choice—low resistance rates, minimal collateral damage) 6, 2
• Trimethoprim-sulfamethoxazole 40/200 mg daily (if local resistance <20%)
• Trimethoprim 100 mg daily

Important consideration for an 84-year-old: Nitrofurantoin requires adequate renal function (CrCl >30 mL/min) and should be used cautiously in elderly patients due to potential pulmonary toxicity with long-term use 2. Check baseline renal function before initiating.

Additional Considerations for This Patient

Assess for Complicating Factors

At age 84, evaluate for:

• Post-void residual volume (elevated PVR is a major risk factor in elderly women) 8
• Urinary incontinence or cystocele (both increase rUTI risk in postmenopausal women) 8, 5
• Diabetes control (if diabetic—poor glycemic control increases UTI risk) 8, 5
• Functional status and cognitive impairment (may present with atypical symptoms like confusion or falls) 9

Imaging Considerations

Do not routinely obtain imaging unless she has: rapid recurrence within 2 weeks of treatment, persistent symptoms despite appropriate therapy, gross hematuria after infection resolution, or symptoms suggesting upper tract involvement 8. The ACR Appropriateness Criteria state imaging has low yield in patients responding promptly to therapy without risk factors 8.

Behavioral Modifications

Reinforce:

• Adequate hydration (promotes frequent urination and pathogen clearance) 8, 6
• Urge-initiated voiding (avoid prolonged bladder distention)
• Proper perineal hygiene

What NOT to Do

• Do not treat asymptomatic bacteriuria—this is common in elderly women (prevalence increases with age) and treatment fosters resistance without reducing symptomatic UTI episodes 6, 9
• Do not classify her as having "complicated" UTI unless structural/functional abnormalities are identified—this leads to unnecessary broad-spectrum antibiotics 6
• Do not continue D-mannose given the strong negative evidence from recent trials 2, 3, 4

Cranberry Products: Weak Alternative

While the 2024 EAU guidelines suggest cranberry products may reduce rUTI episodes, they explicitly note the evidence quality is low with contradictory findings 1. The 2025 AUA guidelines give cranberry a "moderate" recommendation, but emphasize products must contain ≥36 mg proanthocyanidins (PACs) 2. Most commercial products don't document PAC content. Given your patient's age and the availability of stronger evidence-based alternatives, cranberry is not a priority addition.

Monitoring Strategy

• Obtain urine culture before treating each suspected UTI to guide antibiotic selection and track resistance patterns 1, 6
• If persistent symptoms despite treatment, repeat culture before prescribing additional antibiotics 6
• Re-evaluate prophylaxis strategy at 3-6 month intervals 8

Bottom line: Discontinue D-mannose, continue vaginal estrogen, add methenamine hippurate, and escalate to immunoprophylaxis or antibiotic prophylaxis if needed, while carefully assessing for age-related complicating factors in this 84-year-old patient.